Patent US5155215A successfully refreshed from Google Patents.
US5155215A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polychelating agents for image and spectral enhancement (and spectral shift)
Assignee: Abeona Therapeutics Inc
•
Filing: 1990-11-07
•
Granted: 1992-10-13
•
Expires: 2010-11-07
Abstract
Abstract The present invention includes an image-enhancing agent comprising a biodegradable, water-soluble polymer, synthetic or naturally derived and having repeating hydrophilic monomeric units with amino or hydroxyl groups. This agent also includes chelating agents comprising functional groups bound to an amino or bydroxyl group of the monomeric units. These chelating agents have a formation constant for divalent or trivalent metal cations of at least about 108 at physiological temperature and pH. This image-enhancing agent is biodegradable to intermediary metabolites, excretable chelates, oligomers, monomers or combinations thereof of low toxicity. These image-enhancing agents may further comprise a paramagnetic metal ion for enhancement of the image arising from induced magnetic resonance signals. Images resulting from scanning of gamma particle emissions may be enhanced when the image-enhancing agent of the present invention comprise radioisotopic metal ions emitting gamma particles. The physical conversion of these image enhancing agents into microspheres allows further internal directioning of the image-enhancing agents to organs with phogocytic capabilities. Dextran is a preferred polymer DTPA and gadoliniium are respectively preferred chelating agents and paramagnetic metal ions.
Inventors
- 👤 David F. Ranney
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 13:28
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/06; A61K49/08; A61K49/10; A61K49/12; A61K49/126; A61K49/128; A61K49/085; A61K49/18; A61K49/1818; A61K51/00; A61K51/02; A61K51/04; A61K51/06; A61K51/065; A61K51/12; A61K51/1241; A61K51/1255; A61K2123/00
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
124 words
An image-enhancing agent or spectral enhancing agent for in vivo use to improve images arising from induced magnetic resonance signals, the agent consisting essentially of: a biodegradable, water-soluble; dextran, heparin, heparan sulfate, chondroitin sulfate, dermatan sulfate, or DEAE-dextran polymeric carrier-material; a DTPA chelating agent comprising a functional group bound to an amino or hydroxyl group of the dextran, heparin, heparan sulfate, chondroitin sulfate, dermatan sulfate, or DEAE-dextran, said chelating agent having a formation constant for divalent or trivalent metal cations at physiological temperature and pH, of at least about 10 13 ; and a paramagnetic metal ion bound to the chelating agent; wherein the image-enhancing agent, is water-soluble, and biodegradable to intermediary metabolites, excretable chelates, oligomers, monomers or combinations thereof, all of low toxicity.
Claim 2
Dependent Claim
124 words
An image-enhancing agent or spectral enhancing agent for in vivo use to improve images arising from induced magnetic resonance signals, the agent consisting essentially of: a biodegradable, water-soluble; dextran, heparin, heparan sulfate, chondroitin sulfate, dermatan sulfate, or DEAE-dextran polymeric carrier-material; a DTPA chelating agent comprising a functional group bound to an amino or hydroxyl group of the dextran, heparin, heparan sulfate, chondroitin sulfate, dermatan sulfate, or DEAE-dextran, said chelating agent having a formation constant for divalent or trivalent metal cations at physiological temperature and pH, of at least about 10 13 ; and a paramagnetic metal ion bound to the chelating agent; wherein the image-enhancing agent, is water-soluble, and biodegradable to intermediary metabolites, excretable chelates, oligomers, monomers or combinations thereof, all of low toxicity.
Claim 3
Dependent Claim
29 words
The image-enhancing agent of claim 1 wherein the carrier-material is dextran, the chelating agent is DTPA and the carrier-material has a molecular weight of less than about 300,000 daltons.
Claim 4
Dependent Claim
21 words
The image-enhancing agent of claim 1 wherein the carrier-material has a molecular weight between about 1,000 daltons and about 2,000,000 daltons.
Claim 5
Dependent Claim
21 words
The image-enhancing agent of claim 1 wherein the carrier-material has a molecular weight between about 40,000 daltons and about 75,000 daltons.
Claim 6
Dependent Claim
11 words
The image-enhancing agent of claim 1 wherein the carrier-material is dextran.
Claim 7
Dependent Claim
19 words
The image-enhancing agent of claim 1 wherein the functional group is bound by a covalent linkage to the carrier-material.
Claim 8
Dependent Claim
20 words
The image-enhancing agent of claim 1 wherein the functional group is a carboxyl and is bound by an ester linkage.
Claim 9
Dependent Claim
12 words
The image-enhancing agent of claim 1 wherein the chelating agent is DTPA.
Claim 10
Dependent Claim
17 words
The image-enhancing agent of claim 1 wherein the paramagnetic metal ion is gadolinium, iron, chromium or manganese.
Claim 11
Dependent Claim
13 words
The image-enhancing agent of claim 1 wherein the paramagnetic metal ion is gandolinium.
Claim 12
Dependent Claim
21 words
The image-enhancing agent of claim 1 wherein the chelating agent is DTPA and the paramagnetic metal ion is gadolinium or iron.
Claim 13
Dependent Claim
23 words
The image-enhancing agent of claim 1 wherein the carrier-material is dextran, the paramagnetic metal ion is gadolinium, and the chelating agent is DTPA.
Claim 14
Dependent Claim
11 words
The image-enhancing agent of claim 1 wherein the carrier-material comprises heparin.
Claim 15
Dependent Claim
20 words
The image-enhancing agent of claim 1 wherein the polysaccharide is heparin, heparan sulfate, chondroitin sulfate, dermatan sulfate, or DEAE dextran.
Claim 16
Dependent Claim
13 words
The image-enhancing agent of claim 1 wherein the carrier-material comprises heparin and DEAE-dextran.
Claim 17
Dependent Claim
28 words
The image-enhancing agent of claim 1 wherein the carrier-material comprises DEAE-dextran and heparin and the image-enhancing agent further comprises chelating agents bound to the DEAE-dextran by ion-pair bonding.
Claim 18
Dependent Claim
11 words
The image-enhancing agent of claim 1 wherein the carrier-material is heparin.
Claim 19
Dependent Claim
20 words
A magnetic resonance image-enhancing agent consisting essentially of dextran, DTPA bound to said dextran, and gadolinium bound to said DTPA.
Claim 20
Dependent Claim
20 words
A magnetic resonance image-enhancing agent consisting essentially of dextran, DTPA bound to said dextran, and gadolinium bound to said DTPA.
Claim 21
Dependent Claim
21 words
The magnetic resonance image-enhancing agent of claim 18 wherein the dextran has a molecular weight between 1,000 daltons and 2,000,000 daltons.
Claim 22
Dependent Claim
23 words
The magnetic resonance image-enhancing agent of claim 18 wherein the dextran has a molecular weight between about 40,000 daltons and about 75,000 daltons.
Claim 23
Dependent Claim
19 words
The magnetic resonance image-enhancing agent of claim 18 defined further as being at least about 5 weight percent DTPA.
Claim 24
Dependent Claim
67 words
An image-enhancing agent or spectral enhancing agent for in vivo use to improve images arising from induced magnetic resonance signals, the agent consisting essentially of: a biodegradable, water-soluble dextran having monomeric units and a size of less than about 300,000 daltons; at least one DTPA bound to a dextran hydroxyl group for every 7.2 monomeric dextran units; and an iron or gadolinium cation bound to said DTPA.
Claim 25
Dependent Claim
67 words
An image-enhancing agent or spectral enhancing agent for in vivo use to improve images arising from induced magnetic resonance signals, the agent consisting essentially of: a biodegradable, water-soluble dextran having monomeric units and a size of less than about 300,000 daltons; at least one DTPA bound to a dextran hydroxyl group for every 7.2 monomeric dextran units; and an iron or gadolinium cation bound to said DTPA.
References Cited (Backward Citations)
GB1529150A
Cited
US4247406A
Cited
US4370476A
Cited
US4647447A
Cited
US4963344B1
Cited
US5021236A
Cited
US4963344A
Cited
US4957939A
Cited
US4452773A
Cited
US4432987A
Cited
US4472509A
Cited
US4731239A
Cited
GB2137612A
Cited
US4423158A
Cited
US4735796A
Cited
WO1985005554A1
Cited
US4639365A
Cited
US4985233A
Cited
EP0184899A1
Cited
US4986980A
Cited
EP0186947A1
Cited
US4735210A
Cited
US4832940A
Cited
US4904479A
Cited
US4770183A
Cited
US4822594A
Cited
US4832877A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-10-13 | 1996-04-13 | 1996-10-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-10-13 | 2000-04-13 | 2000-10-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-10-13 | 2004-04-13 | 2004-10-13 | $7700.00 | Window Closed / Lapsed |